How do I subscribe to ongoing alerts?

Subscribe to /feed/company/centre-de-recherche-de-l-institut-universitaire-de-cardiologie-et-de-pneumologie.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec pipeline: 9 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

9 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Atorvastatin-ranitidine	Atorvastatin-ranitidine	marketed
Rosuvastatin-esomeprazole	Rosuvastatin-esomeprazole	marketed
Atorvastatin-pantoprazole	Atorvastatin-pantoprazole	marketed
Rosuvastatin-pantoprazole	Rosuvastatin-pantoprazole	marketed	Statin + proton pump inhibitor combination	HMG-CoA reductase (rosuvastatin); H+/K+-ATPase (pantoprazole)	Cardiovascular
Atorvastatin-omeprazole	Atorvastatin-omeprazole	marketed	Fixed-dose combination (statin + proton pump inhibitor)	HMG-CoA reductase (atorvastatin); H+/K+-ATPase (omeprazole)	Cardiovascular
Atorvastatin-esomeprazole	Atorvastatin-esomeprazole	marketed	Statin + proton pump inhibitor combination	HMG-CoA reductase; H+/K+-ATPase	Cardiovascular
Rosuvastatin-omeprazole	Rosuvastatin-omeprazole	marketed	Statin + proton pump inhibitor combination	HMG-CoA reductase (rosuvastatin); H+/K+-ATPase (omeprazole)	Cardiovascular
Rivaroxaban, dabigatran, apixaban, or edoxaban	Rivaroxaban, dabigatran, apixaban, or edoxaban	marketed	Direct oral anticoagulant (DOAC)	Factor Xa (rivaroxaban, apixaban, edoxaban) or Thrombin (dabigatran)	Cardiovascular
Rosuvastatin-ranitidine	Rosuvastatin-ranitidine	marketed	Fixed-dose combination: HMG-CoA reductase inhibitor + H2-receptor antagonist	HMG-CoA reductase (rosuvastatin component); Histamine H2 receptor (ranitidine component)	Cardiovascular

Therapeutic area mix

Cardiovascular · 6

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Centre Hospitalier Universitaire de Nīmes · 1 shared drug class
Johns Hopkins University · 1 shared drug class
University Hospital, Brest · 1 shared drug class
University Hospital, Grenoble · 1 shared drug class
University of Sao Paulo General Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec:

Cite this brief

Drug Landscape (2026). Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centre-de-recherche-de-l-institut-universitaire-de-cardiologie-et-de-pneumologie. Accessed 2026-05-17.